Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, a substantial increase from $2 million in the year-ago period. The growth was driven by approximately $11 million in net sales of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the company's recently approved treatment for fibromyalgia. During the quarter, TONMYA recorded 12,592 total prescriptions, up 100% sequentially, with new patient prescriptions increasing 36% and refills rising 207%. This commercial momentum underscores the drug's market acceptance and the company's successful launch strategy.
TONMYA currently has coverage representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. This coverage is expected to expand to approximately 145 million lives when a managed Medicare agreement takes effect on Jan. 1, 2027, further broadening patient access to the first new fibromyalgia treatment in over 15 years. The company's CNS commercial infrastructure, which also supports its acute migraine products Zembrace SymTouch and Tosymra, is positioned to maximize TONMYA's market potential.
Beyond commercial progress, Tonix continues to advance its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder. Additionally, Tonix is preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. These programs highlight the company's commitment to addressing high unmet medical needs in CNS and immunology.
The company ended the quarter with approximately $176.2 million in cash and cash equivalents. According to management, these resources, together with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This financial position provides a runway to execute on key milestones, including the continued commercialization of TONMYA and the advancement of its pipeline.
The robust sales of TONMYA represent a critical inflection point for Tonix, transitioning from a development-stage company to a commercial-stage biotech. The significant revenue growth and expanding insurance coverage are likely to attract investor attention and could pave the way for sustained growth. As the company continues to invest in clinical trials and commercial infrastructure, its ability to generate revenue from TONMYA will be essential for long-term success.
